I kliniske studier var størrelsen af HbA1c- reduktionerne med vildagliptin større hos patienter med højere baseline HbA 1c.
In clinical trials, the magnitude of HbA 1c reductions with vildagliptin was greater in patients with higher baseline HbA 1c.